Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03736967 · Regeneron Pharmaceuticals · PHASE2 · terminated · last registry update 2021-11-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, Regeneron Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-06-10Results posted on the registry: Regeneron Pharmaceuticals, REGN3500 + REGN3500-Matching Placebo (NCT03738423)
- 2022-06-10Also stopped (terminated): Regeneron Pharmaceuticals, REGN3500 + REGN3500-Matching Placebo (NCT03738423)
- 2022-03-29Results posted on the registry: Sanofi, SAR440340 + Dupilumab (NCT03387852)
- 2022-01-24Results posted on the registry: AnaptysBio, Inc., Etokimab + Placebo (NCT03614923)
- 2021-02-12Phase 3 first posted: Sanofi, Itepekimab SAR440340 + Placebo (NCT04751487)
- 2021-01-08Phase 3 first posted: Sanofi, Itepekimab SAR440340 + Placebo (NCT04701983)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision